Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 91,084,216
  • Shares Outstanding, K 2,527,310
  • Annual Sales, $ 16,060 M
  • Annual Income, $ 5,187 M
  • 36-Month Beta 0.82
  • Price/Sales 5.50
  • Price/Book 14.69

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.84 +2.27%
on 01/12/17
37.08 -3.91%
on 01/05/17
+0.22 (+0.62%)
since 12/19/16
3-Month
30.89 +15.34%
on 11/23/16
41.65 -14.45%
on 10/21/16
-4.86 (-12.00%)
since 10/19/16
52-Week
30.89 +15.34%
on 11/23/16
57.81 -38.37%
on 04/19/16
-17.57 (-33.03%)
since 01/19/16

Most Recent Stories

More News
Drug Makers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Sucampo Pharma, and Pernix Therapeutics

Stock-Callers.com today evaluates the following Drug Manufacturers equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), and...

North America Insulin Delivery Market Outlook to 2022 - Key Players are Medtronic, Becton Dickinson and Co, Eli Lilly and Company, Insulet & Novo Nordisk - Research and Markets

Research and Markets has announced the addition of the "North America Insulin Delivery Market Outlook to 2022" report to their offering.

NVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Novo Nordisk A/S (NYSE:NVO) securities...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:NVO) and certain of its...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Novo Nordisk A/S - NVO

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Novo Nordisk A/S securities (NYSE:NVO) from April 30, 2015 through...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Novo Nordisk A/S of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - NVO

The following statement is being issued by Levi & Korsinsky, LLP:

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017

NEW YORK, NY / ACCESSWIRE / January 12, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:...

Global Diabetes Market: Industry Analysis & Outlook 2016-2020 Featuring Sanofi, Takeda, Eli Lilly & Novo Nordisk - Research and Markets

Research and Markets has announced the addition of the "Global Diabetes Market: Industry Analysis & Outlook (2016-2020)" report to their offering.

Global Hemophilia Treatment Drugs Market to be Worth US$25.1 Billion by 2024: FDA Approvals for Testing Novel Drugs Opens up Opportunities, Says TMR

ALBANY, New York, January 12, 2017 /PRNewswire/ --

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Novo Nordisk A/S To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE:NVO) of the March 13, 2017 deadline to seek the role of lead...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 35.94
1st Resistance Point 35.78
Last Price 35.63
1st Support Level 35.52
2nd Support Level 35.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.